Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News


What is Nucleus?: A Webinar w/ CEO, Logan Lenz

Join the CEO of Nucleus, Logan Lenz, as he explains Nucleus in the simplest terms. Investing in Nucleus For those who don’t know, Nucleus currently allows anyone to invest in the company with as little as $200. All you must do is visit the Wefunder page, select your investment amount, and go through Wefunder’s transaction…


Which Psychedelic Compound Are You?: Mindshifting Moments #19

Host Margaret Williamson is joined by Shannon Starr of Floresta Retreat. During this episode, the two chat about all of the attributes of psychedelic compounds. To add to the fun, we even made a quiz. “Which psychedelic medicine is right for you?” More About Floresta Retreat Psychedelic & Indigenous Medicine Retreat Floresta is a team…

Lobe Sciences Press

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

obe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130. “Subsequent to our last communication on the cGMP production of L-130, I wanted…

Wellbeing-Digital-Sciences Press

Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc., has submitted a clinical trial application (“CTA”) on behalf of client…


FSD Pharma Inc. Announces Changes to the Board of Directors

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FSE: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced the appointments of Dr. Lakshmi P. Kotra and Joseph L. Romano to its board of directors, effective Nov. 25, 2022. Effective at the…

Psyence Press

GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd, entered into an exclusive distribution agreement with This Works Products Limited for the distribution and sale…

Mindset Pharma Press

Mindset Pharma CEO, James Lanthier Issues Letter to Shareholders

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset. Dear Fellow Shareholders: As we approach the end of 2022, I would like to take a moment to remind both shareholders and the broader investment community of Mindset’s recent accomplishments since our last…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.